New hope for Tough-to-Treat lymphoma: experimental drug combo enters phase 3 trial

NCT ID NCT07562022

Recruiting now Disease control Sponsor: Sinocelltech Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This Phase 3 trial tests whether a new drug called SCTB35, combined with lenalidomide, works better than the standard rituximab-plus-lenalidomide combo for people with follicular lymphoma that has returned or not responded to treatment. About 93 adults aged 18-80 will take part. The study will measure side effects, how long the cancer stays under control, and overall response rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SCTB35 (an experimental drug) combined with lenalidomide
What this could lead to: If successful, this could offer a new treatment option for people with follicular lymphoma that has returned or not responded to prior therapy.
What could go wrong: This is an early-stage Phase 3 trial with only 93 participants, so results may not apply to all patients. The experimental drug SCTB35 may cause side effects or not work better than the standard combination.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA (FL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOLLICULAR LYMPHOMA (FL)

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.